866-997-4948(US-Canada Toll Free)

Myelodysplastic Syndrome - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Oncology

No. of Pages : 242 Pages


Global Markets Directs, \'Myelodysplastic Syndrome Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Myelodysplastic Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome. 

Myelodysplastic Syndrome Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Myelodysplastic Syndrome.
  • A review of the Myelodysplastic Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Myelodysplastic Syndrome pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Myelodysplastic Syndrome.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Myelodysplastic Syndrome pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 6
Introduction 8
Global Markets Direct Report Coverage 8
Myelodysplastic Syndrome Overview 9
An Overview of Pipeline Products for Myelodysplastic Syndrome 10
Myelodysplastic Syndrome Therapeutics under Development by Companies 12
Myelodysplastic Syndrome Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 19
Comparative Analysis 19
Mid Clinical Stage Products 20
Comparative Analysis 20
Early Clinical Stage Products 21
Comparative Analysis 21
Discovery and Pre-Clinical Stage Products 22
Comparative Analysis 22
Myelodysplastic Syndrome Therapeutics - Products under Development by Companies 23
Myelodysplastic Syndrome Therapeutics - Products under Investigation by Universities/Institutes 26
Companies Involved in Myelodysplastic Syndrome Therapeutics Development 28
Bristol-Myers Squibb Company 28
F. Hoffmann-La Roche Ltd. 29
Amgen Inc. 30
Sanofi-Aventis 31
MedImmune LLC 32
medac GmbH 33
Gamida Cell Ltd. 34
Bio-Path Holdings, Inc. 35
Millennium Pharmaceuticals, Inc. 36
Novartis AG 37
Pfizer Inc. 38
Enzon Pharmaceuticals, Inc. 39
Incyte Corporation 40
Access Pharmaceuticals, Inc. 41
4SC AG 42
Hana Biosciences, Inc. 43
IMMUNOMEDICS, INC 44
Ariad Pharmaceuticals, Inc. 45
Jazz Pharmaceuticals, Inc. 46
Portola Pharmaceuticals, Inc. 47
Mundipharma International Limited 48
MorphoSys AG 49
Lipoxen PLC 50
Threshold Pharmaceuticals, Inc. 51
Sareum Holdings plc 52
Oryzon 53
ERYtech Pharma 54
Aileron Therapeutics, Inc. 55
CanBas Co., Ltd. 56
Deciphera Pharmaceuticals, LLC 57
Cornerstone Pharmaceuticals, Inc. 58
Onconova Therapeutics, Inc 59
TcL Pharma SAS 60
Syndax Pharmaceuticals, Inc. 61
Omeros Corporation 62
Tragara Pharmaceuticals, Inc. 63
Sigma-Tau Pharmaceuticals, Inc. 64
Interprotein Corporation 65
EpiZyme, Inc. 66
Myelodysplastic Syndrome - Therapeutics Assessment 67
Assessment by Monotherapy Products 67
Assessment by Combination Products 68
Drug Profiles 69
StemEx - Drug Profile 69
entinostat - Drug Profile 71
pevonedistat - Drug Profile 74
midostaurin - Drug Profile 75
SAR-3419 - Drug Profile 77
moxetumomab pasudotox - Drug Profile 78
blinatumomab - Drug Profile 79
ponatinib - Drug Profile 82
Thiarabine - Drug Profile 84
4SC-202 - Drug Profile 86
ENZ-3042 - Drug Profile 88
asparaginase - Drug Profile 89
TG-02 - Drug Profile 91
ruxolitinib - Drug Profile 93
vincristine sulfate - Drug Profile 97
vincristine sulfate - Drug Profile 100
vincristine sulfate - Drug Profile 103
vincristine sulfate - Drug Profile 106
forodesine - Drug Profile 109
TH-302 - Drug Profile 111
ON-013105 - Drug Profile 113
MD-707 - Drug Profile 114
RG-7112 - Drug Profile 115
MOR-208 - Drug Profile 117
interferon alfa-2b + GM-CSF - Drug Profile 118
epratuzumab - Drug Profile 119
bortezomib + [cytarabine] + [etoposide] + [mitoxantrone hydrochloride] - Drug Profile 123
clioquinol - Drug Profile 125
Donor Lymphocyte Infusion + Aldesleukin - Drug Profile 126
CTL-019 - Drug Profile 128
PF-03084014 - Drug Profile 129
genetically modified T cells - Drug Profile 130
inotuzumab ozogamicin - Drug Profile 131
c-Myb AS ODN - Drug Profile 133
BP-100-1.01 - Drug Profile 134
rebastinib - Drug Profile 136
Recombinant asparaginase - Drug Profile 138
iodine I 131 Monoclonal Antibody BC8 + mycophenolate mofetil + tacrolimus + [cyclophosphamide] + [fludarabine phosphate] + Total-body irradiation + allogeneic bone marrow transplantation - Drug Profile 139
belinostat + [bortezomib] - Drug Profile 141
epratuzumab + veltuzumab [asparaginase] + [daunorubicin] + [dexamethasone] + [methotrexate] + [vincristine sulfate] - Drug Profile 142
Allodepleted T Cells - Drug Profile 144
Umbilical Cord Blood Transplantation - Drug Profile 145
asparaginase erwinia chrysanthemi - Drug Profile 147
Multi-Virus-Specific Cyototoxic T Lymphocytes - Drug Profile 149
CBS-9106 - Drug Profile 150
entinostat + clofarabine - Drug Profile 152
Sargramostim + Entinostat - Drug Profile 154
Cancer Program - Drug Profile 155
BMS-906024 - Drug Profile 156
panobinostat + [cytarabine hydrochloride] + [idarubicin hydrochloride] - Drug Profile 157
TYK2 Kinase Program - Drug Profile 158
IPC-003 - Drug Profile 159
bortezomib + vorinostat + [dexamethasone] + [imatinib] + [methotrexate] - Drug Profile 160
P2Y8 Antagonist - Drug Profile 161
Interleukin-1 Receptor Associated Protein Targeting Antibody - Drug Profile 162
ORB-0001 - Drug Profile 164
[clofarabine] + cyclophosphamide - Drug Profile 165
calaspargase pegol - Drug Profile 166
lenaldekar - Drug Profile 167
FPI-01 - Drug Profile 168
BXQ-350 - Drug Profile 170
Mastermind Coactivator Protein Derived Stapled Peptides - Drug Profile 172
EPZ-5676 - Drug Profile 173
Autologous CD19 CAR + EGFTt + T Cells - Drug Profile 174
TGR-1202 - Drug Profile 175
PRT-060318 - Drug Profile 177
Mer Kinase Inhibitors - Drug Profile 178
Myelodysplastic Syndrome Therapeutics - Drug Profile Updates 179
Myelodysplastic Syndrome Therapeutics - Discontinued Products 224
Myelodysplastic Syndrome Therapeutics - Dormant Products 226
Myelodysplastic Syndrome - Product Development Milestones 229
Featured News & Press Releases 229

Appendix 237
Methodology 237
Coverage 237
Secondary Research 237
Primary Research 237
Expert Panel Validation 237
Contact Us 238
Disclaimer 238

List of Table


Number of Products Under Development for Myelodysplastic Syndrome, H1 2013 14
Products under Development for Myelodysplastic Syndrome - Comparative Analysis, H1 2013 15
Number of Products under Development by Companies, H1 2013 17
Number of Products under Development by Companies, H1 2013 (Contd..1) 18
Number of Products under Development by Companies, H1 2013 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2013 21
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 22
Comparative Analysis by Late Stage Development, H1 2013 23
Comparative Analysis by Mid Clinical Stage Development, H1 2013 24
Comparative Analysis by Early Clinical Stage Development, H1 2013 25
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 26
Products under Development by Companies, H1 2013 27
Products under Development by Companies, H1 2013 (Contd..1) 28
Products under Development by Companies, H1 2013 (Contd..2) 29
Products under Investigation by Universities/Institutes, H1 2013 30
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 31
Bristol-Myers Squibb Company, H1 2013 32
F. Hoffmann-La Roche Ltd., H1 2013 33
Amgen Inc., H1 2013 34
Sanofi-Aventis, H1 2013 35
MedImmune LLC, H1 2013 36
medac GmbH, H1 2013 37
Gamida Cell Ltd., H1 2013 38
Bio-Path Holdings, Inc., H1 2013 39
Millennium Pharmaceuticals, Inc., H1 2013 40
Novartis AG, H1 2013 41
Pfizer Inc., H1 2013 42
Enzon Pharmaceuticals, Inc., H1 2013 43
Incyte Corporation, H1 2013 44
Access Pharmaceuticals, Inc., H1 2013 45
4SC AG, H1 2013 46
Hana Biosciences, Inc., H1 2013 47
IMMUNOMEDICS, INC, H1 2013 48
Ariad Pharmaceuticals, Inc., H1 2013 49
Jazz Pharmaceuticals, Inc., H1 2013 50
Portola Pharmaceuticals, Inc., H1 2013 51
Mundipharma International Limited, H1 2013 52
MorphoSys AG, H1 2013 53
Lipoxen PLC, H1 2013 54
Threshold Pharmaceuticals, Inc., H1 2013 55
Sareum Holdings plc, H1 2013 56
Oryzon, H1 2013 57
ERYtech Pharma, H1 2013 58
Aileron Therapeutics, Inc., H1 2013 59
CanBas Co., Ltd., H1 2013 60
Deciphera Pharmaceuticals, LLC, H1 2013 61
Cornerstone Pharmaceuticals, Inc., H1 2013 62
Onconova Therapeutics, Inc, H1 2013 63
TcL Pharma SAS, H1 2013 64
Syndax Pharmaceuticals, Inc., H1 2013 65
Omeros Corporation, H1 2013 66
Tragara Pharmaceuticals, Inc., H1 2013 67
Sigma-Tau Pharmaceuticals, Inc., H1 2013 68
Interprotein Corporation, H1 2013 69
EpiZyme, Inc., H1 2013 70
Assessment by Monotherapy Products, H1 2013 71
Assessment by Combination Products, H1 2013 72
Myelodysplastic Syndrome Therapeutics - Drug Profile Updates 183
Myelodysplastic Syndrome Therapeutics - Discontinued Products 228
Myelodysplastic Syndrome Therapeutics - Discontinued Products (Contd..1) 229
Myelodysplastic Syndrome Therapeutics - Dormant Products 230
Myelodysplastic Syndrome Therapeutics - Dormant Products (Contd..1) 231
Myelodysplastic Syndrome Therapeutics - Dormant Products (Contd..2) 232

List of Chart


Number of Products under Development for Myelodysplastic Syndrome, H1 2013 14
Products under Development for Myelodysplastic Syndrome - Comparative Analysis, H1 2013 15
Products under Development by Companies, H1 2013 16
Products under Investigation by Universities/Institutes, H1 2013 20
Late Stage Products, H1 2013 23
Mid Clinical Stage Products, H1 2013 24
Early Clinical Stage Products, H1 2013 25
Discovery and Pre-Clinical Stage Products, H1 2013 26
Assessment by Monotherapy Products, H1 2013 71
Assessment by Combination Products, H1 2013 72

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *